研究健康受试者空腹单次口服受试制剂阿仑膦酸钠片（海南全星制药有限公司，规格：70mg）与参比制剂阿仑膦酸钠片（商品名：Fosamax ®，MSD PHARMA（SINGAPORE） PTE. LTD.，规格：70mg）在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹状态下给药时的生物等效性趋势，为正式试验提供依据，观察受试制剂和参比制剂在健康受试者中的安全性。

开始日期2024-06-09

申办/合作机构

海南全星制药有限公司

ChiCTR2400082213 / Suspended早期临床1期IIT

Study on the Influencing Factors of the Effect of Sodium Alendronate Combined with Calcium Carbonate D3 in Improving Bone Density in Maintenance Hemodialysis Patients with Renal Osteodystrophy.

开始日期2024-05-01

申办/合作机构-

NCT06016634 / Not yet recruiting临床2期IIT

A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

开始日期2024-03-01

申办/合作机构

University of California, Davis

[+2]

100 项与阿仑膦酸钠相关的临床结果

登录后查看更多信息

100 项与阿仑膦酸钠相关的转化医学

登录后查看更多信息

100 项与阿仑膦酸钠相关的专利（医药）

登录后查看更多信息

5,203

项与阿仑膦酸钠相关的文献（医药）

2024-04-01·International journal of clinical pharmacy

The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies

Review

作者: Oliveira, Tânia ; Alves, Carlos ; Donato, António ; Batel-Marques, Francisco ; Mendes, Diogo ; Penedones, Ana

Abstract:

Background:

Ibandronate is effective in reducing the risk of vertebral fractures, but experimental evidence offers conflicting results regarding nonvertebral fractures. Real-world evidence has been published evaluating the anti-nonvertebral fracture effect of ibandronate.

Aim:

This meta-analysis of observational studies assessed the effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis.

Method:

Pubmed/Embase databases were searched for observational studies. Risks of nonvertebral fractures and hip fractures were the outcomes. Meta-analyses were performed pooling rate ratios (RRs), using random-effects models. Data were reanalysed in sensitivity analyses considering Knapp–Hartung method and Bayesian random-effects.

Results:

Six cohort studies were included. Overall, once-monthly 150 mg oral ibandronate reduced the risk of nonvertebral fractures (RR 0.84; 95% CI 0.76–0.94). Similar results were obtained when the comparison was restricted to once-monthly 150 mg risedronate, but no differences were found when the comparator was other oral bisphosphonates (weekly alendronate/risedronate). Ibandronate didn’t significantly change the risk of hip fractures (RR 1.25; 95% CI 0.89–1.76). The risk of hip fracture was comparable between once monthly, 150 mg oral ibandronate and other oral bisphosphonates. Intravenous ibandronate was not effective in reducing hip fractures comparing to intravenous zoledronate. The low number of studies diminished the robustness of sensitivity analyses.

Conclusion:

Results suggest that once-monthly 150 mg oral ibandronate may be as effective as other oral bisphosphonates in reducing the risk of nonvertebral fractures. However, uncertainty associated to the small number of included studies, which are characterized by heterogeneous demographics and methodologies, precluded definitive conclusions.

2024-04-01·Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level

Article

作者: Chavassieux, P ; Chapurlat, R ; Roux, J P

PURPOSE:

The main effect of anti-resorptive agents such as bisphosphonates is a reduction of bone resorption, with a consequent marked decrease of bone turnover. This post-hoc analysis investigated the changes of histomorphometric parameters of bone turnover after alendronate (ALN), according to the baseline turnover.

METHODS:

Ninety postmenopausal women underwent a transiliac bone biopsy before and after 6 (n = 44) or 12 (n = 46) months of treatment with ALN (70 mg/week). The dynamic parameters reflecting the bone formation and bone turnover were mineralizing surface (MS/BS; %), bone formation rate (BFR/BS; μm³/μm²/d), and activation frequency (Ac.f; /yr). Biochemical markers sPINP and the sCTX were assessed before treatment and after 3, 6, and 12 months. Subjects were divided into quartiles based on the baseline values of BFR/BS.

RESULTS:

At baseline, MS/BS and Ac.f were significantly different (p < 0.0001) among the BFR quartiles. sCTX and sP1NP were not significantly different among quartiles. After ALN treatment, MS/BS was not significantly different among quartiles but Ac.f remained significantly lower in the first quartile compared to the third and fourth ones (p < 0.03). The absolute value of the difference between pre- and post-treatment significantly correlated with the baseline BFR/BS but when expressed in percent of the baseline value, the magnitude of the diminutions of MS/BS, Ac.f, sCTX, and sP1NP was similar in the four baseline BFR quartiles.

CONCLUSION:

The percentage response to ALN appeared independent of the baseline level of bone turnover. After treatment, the bone turnover tended to be similar in all BFR quartiles. This analysis investigated the influence of baseline turnover measured by bone histomorphometry on the effect of alendronate. When expressed in percent of pre-treatment values, the decreases of histomorphometric parameters and biochemical markers of bone turnover were independent of the baseline turnover.

2024-04-01·Retina (Philadelphia, Pa.)

DIAGNOSTIC AND THERAPEUTIC CHALLENGES

Article

作者: Sharma, Sumit ; Hay, Gordon ; Testi, Ilaria ; Szigiato, Andrei-Alexandru ; Sullivan, Paul ; Pavesio, Carlos

The case of a 37-yr-old, married, white man presented to the Wilmer Eye Institute in Apr. 2009 reporting persistent halos and blurriness in his vision on both eyes for 1 wk, was presented.The patient was on a regimen of medications for sarcoid and its multiorgan involvements, including prednisone, amiodarone for atrial fibrillation, metoprolol for hypertension, alendronate sodium for osteoporosis, and pantoprazole for gastroesophageal reflux disease.Several experts, particularly Drs. Narsing A. Rao and Daniel V. Vasconcelos-Santos, and Dr. Debra A. Goldstein, were asked for their opinion regarding the case.A diagnosis of amiodarone optic neuropathy was made for the 37-yr-old white man.Amiodarone was discontinued, while the active sarcoidosis was treated with methotrexate, and his prednisone was slowly tapered.The patient returned 2 mo after initial visits for follow-up.The patient continued to be followed-up every 2-mo to 4-mo interval.At the 1-yr visit, the ocular symptoms had remained stable, but, the patient developed worsened arrhythmia, which was initially treated with ablation therapy, but it was not successful and required five sessions of elec. shocks.He was put on sotalol for treatment of the arrhythmia.It was thought that the activity of the sarcoidosis had increased.His methotrexate was discontinued, and he was started on mycophenolate mofetil.Fortunately, there had not been any progression of his ocular findings.

项与阿仑膦酸钠相关的新闻（医药）

2024-06-25

·BioSpace

Radius Pharmaceuticals Announces the Appointment of Renata Sklodowska, M.D. as Senior Vice President of Medical Operations

BOSTON, MA / ACCESSWIRE / June 25, 2024 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced the appointment of Renata Sklodowska, M.D. as Senior Vice President, Medical Operations. Dr. Sklodowska joins Radius with over fifteen years of clinical development, regulatory, and medical affairs experience. She will report to Scott Briggs, Chief Executive Officer, and will oversee Medical Operations including Medical Affairs, Regulatory Affairs, and Pharmacovigilance (PV). "I am very pleased to welcome Renata to our Executive Leadership Team at Radius," said Scott. "Renata's extensive pharmaceutical industry experience, as well as her strong leadership track record in global medical and scientific affairs, will be extremely valuable as Radius continues to build its presence in bone health and related areas. Of particular importance will be Renata's strong patient-focus and ability to build alliances with medical, scientific, and patient communities to support our efforts with TYMLOS® and BINOSTO®." Dr. Sklodowska is an accomplished international pharmaceutical and biotech executive with Medical and Scientific Affairs expertise,as well as commercial experience. Her tenure includes more than fifteen years in the rare diseases area, including Endocrinology, with proven success preparing and supporting successful product launches as well as managing product portfolios. Dr. Sklodowska has an established history leading Medical Affairs activities for development stage and marketed drugs and a tested ability to create, train, and lead cross-functional teams to attain business objectives. Dr. Sklodowska has established global PV systems and provided oversight for the PV, drug safety, and risk management activities for numerous marketed products. As part of her responsibilities, she will also provide important scientific and medical expertise and guidance to support therapeutic area and product assessments behind business development efforts at Radius. "I look forward to joining the Radius team and applying my years of experience to build upon the company's successes to date, and to not only support TYMLOS® and BINOSTO®, but to also provide medical and strategic insight to explore opportunities to expand the Radius portfolio over time," stated Dr. Sklodowska. Prior to joining Radius, Dr. Sklodowska held several leadership positions in clinical development and medical affairs at biotech and global pharmaceutical companies, having most recently served as Vice President of Medical Affairs at F2G and Recordati Rare Diseases. Dr. Sklodowska received her Doctor of Medicine degree from the Medical University of Bialystok, Poland where she was also an attending physician. About Radius: Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also recently announced an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company's presence in bone health. Contact: Sara Goldberg: Head of Communications Email: corporatecommunications@radiuspharm.com Phone: +1 (631) 379-8374 SOURCE: Radius Health, Inc. View the original press release on accesswire.com

高管变更引进/卖出上市批准

2024-06-05

·Science Daily

Bone loss drugs can help azoles fight fungal infections

A new study suggests that adding common bone loss drugs to azoles can improve efficacy when treating fungal infections. Human skin, hair and nails are all vulnerable to fungal infections. While these infections are usually not serious, they're difficult to fully resolve and often recur after treatment -- sometimes for years. They're also often resistant to treatments, including a common class of antifungals called azoles. A study published this week in mSphere points to a new way to boost the efficacy of azoles in treating those infections -- combining them with commonly available drugs called bisphosphonates, usually used to treat osteoporosis. Previous work by the same research group has shown that adding bisphosphonates to azoles can effectively treat yeast infections from Candida and Cryptococcus species. The new study extends that finding to dermatophytes, which cause superficial infections. The study suggests that bisphosphonates could be repurposed to use with azole antifungals, which are relatively nontoxic, and that the combination could be readily tested in clinical studies. "There aren't many good antifungal drugs around, and the fungus will always develop resistance no matter how you treat them," said senior author Dee Carter, a mycologist at the University of New South Wales, Australia. "For what we're proposing, to use 2 drugs at the same time, that resistance is much less likely." Carter says she was only a little surprised to see the synergistic effect in dermatophytes. This research project began years ago, she says, when her group conducted a series of genomic analyses on the response of pathogenic yeasts to drug treatment. That study led them to a genetic pathway that is "upstream" of the pathway targeted by azoles, and is instead targeted by bisphosphonates. "That's often a good way to get drugs to work, is to target processes that are interlinked like that," Carter said. In the lab, Carter and her team tested 3 commonly available bisphosphonates (risedronate, alendronate and zoledronate) in combination with 3 commonly available azole antifungals (fluconazole, itraconazole and ketoconazole). They tested these against clinical isolates from a diverse range of dermatophyte species that cause superficial infections. The combination of zoledronate and ketoconazole proved particularly effective against 8 of the 9 tested species. It also prevented the development of resistance. Aidan Kane, mycologist, lead author of the study and a Ph.D. student in Carter's lab, used fluorescence microscopy and other methods to show that the drug combination worked by weakening the cell membrane enough that the fungus could not survive. Beyond the dermatophytes, the group also found that bisphosphonate-azole combinations could act against molds that cause invasive disease, suggesting another possible clinical application for the drugs. "You can use these combinations directly for superficial infections, like Candida or dermatophyte infections, and we're hoping that with modified forms of the drugs we can create something that will also work systematically," Carter said. "The next step is to continue testing bisphosphonate-azole combinations in animal models, and then test it in clinical trials."

临床结果

2024-04-22

·信狐药迅

长春金赛曲普瑞林微球新适应症报上市；两家RSV mRNA疫苗首报临床| 新受理（4.15-4.21）

本周药品注册受理数据，分门别类呈现，一目了然。(4.15-4.21）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号盐酸普萘洛尔滴剂四川奥邦古得药业有限公司2.2CXHS2400029注射用醋酸曲普瑞林微球长春金赛药业有限责任公司2.2CXHS2400028新药临床申请药品名称企业注册分类受理号WSD0922-FU片威尚(上海)生物医药有限公司1CXHL2400406WSD0922-FU片威尚(上海)生物医药有限公司1CXHL2400405WSD0922-FU片威尚(上海)生物医药有限公司1CXHL2400404FH-2001胶囊江苏星盛新辉医药有限公司1CXHL2400403HRS-1358片山东盛迪医药有限公司1CXHL2400401HRS-1358片山东盛迪医药有限公司1CXHL2400400HRS-9813片广东恒瑞医药有限公司1CXHL2400397HRS-9813片广东恒瑞医药有限公司1CXHL2400396STC008注射液成都诺和晟泰生物科技有限公司1CXHL2400395YD0293片上海壹典医药科技开发有限公司1CXHL2400399YD0293片上海壹典医药科技开发有限公司1CXHL2400398SYHA1813口服溶液中国科学院上海药物研究所1CXHL2400394SYHA1813口服溶液中国科学院上海药物研究所1CXHL2400393SYHA1813口服溶液中国科学院上海药物研究所1CXHL2400392HJ787片华津(重庆)药业有限公司1CXHL2400389HJ787片华津(重庆)药业有限公司1CXHL2400388HJ787片华津(重庆)药业有限公司1CXHL2400387HJ787片华津(重庆)药业有限公司1CXHL2400386HJ787片华津(重庆)药业有限公司1CXHL2400385HJ787片华津(重庆)药业有限公司1CXHL2400384VIC-1911片捷思英达医药技术(上海)有限公司1CXHL2400376GP681片江西青峰药业有限公司1CXHL2400375GP681片江西青峰药业有限公司1CXHL2400374艾司奥美拉唑镁碳酸氢钠干混悬剂(II)海南广升誉制药有限公司2.2CXHL2400381BR170720口服混悬液山东百诺医药股份有限公司2.2CXHL2400383BCM894胶囊上海云晟研新生物科技有限公司2.3CXHL2400382林普利塞片上海璎黎药业有限公司2.4CXHL2400402海曲泊帕乙醇胺片江苏恒瑞医药股份有限公司2.4CXHL2400391注射用多西他赛(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2400390阿瑞匹坦注射液石药集团中诺药业(石家庄)有限公司3CYHL2400077噻托溴铵吸入粉雾剂长风药业股份有限公司4CYHL2400078注射用LX22001山东罗欣药业集团股份有限公司2.1;2.2CXHL2400378注射用LX22001山东罗欣药业集团股份有限公司2.1;2.2CXHL2400377注射用LX22001山东罗欣药业集团股份有限公司2.1;2.2;2.4CXHL2400380注射用LX22001山东罗欣药业集团股份有限公司2.1;2.2;2.4CXHL2400379呼吸道合胞病毒mRNA疫苗石药集团巨石生物制药有限公司1.2CXSL2400244呼吸道合胞病毒mRNA疫苗合肥阿法纳生物科技有限公司1.2CXSL2400233流感病毒裂解疫苗武汉生物制品研究所有限责任公司3.3CXSL2400248流感病毒裂解疫苗武汉生物制品研究所有限责任公司3.3CXSL2400247EX101注射液广州爱思迈生物医药科技有限公司1CXSL2400252KY-0118注射剂科弈(浙江)药业科技有限公司1CXSL2400254注射用BGB-B2033广州百济神州生物制药有限公司1CXSL2400253重组人源抗破伤风毒素单克隆抗体注射液兰州生物制品研究所有限责任公司1CXSL2400249VPD/FC01008 注射液微能生命科技集团有限公司1CXSL2400250WST03制剂(胶囊)上海上药信谊药厂有限公司1CXSL2400246WST03制剂(胶囊)上海上药信谊药厂有限公司1CXSL2400245FL115注射液苏州复融生物技术有限公司1CXSL2400239TQB2928注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2400238抗CD30嵌合抗原受体自体T细胞注射液明慧(南京)基因生物技术有限公司1CXSL2400242注射用BL-M17D1成都百利多特生物药业有限责任公司1CXSL2400237重组抗PD-1全人源单抗注射液石药集团中奇制药技术(石家庄)有限公司1CXSL2400243重组抗HER3人源化单抗注射液上海生物制品研究所有限责任公司1CXSL2400232BR105注射液杭州博之锐生物制药有限公司1CXSL2400236VPD/FC01002 注射液微能生命科技集团有限公司1CXSL2400235信迪利单抗注射液信达生物制药(苏州)有限公司2.2CXSL2400251司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400241司美格鲁肽注射液正大天晴药业集团股份有限公司3.3CXSL2400240LPS-001注射液乐普药业股份有限公司3.3CXSL2400231静注人免疫球蛋白(pH4)四川远大蜀阳药业有限责任公司3.4CXSL2400234仿制药申请药品名称企业注册分类受理号倍他米松磷酸钠注射液漯河市汇创医药有限公司3CYHS2401190盐酸甲氧氯普胺注射液山东如至生物医药科技有限公司3CYHS2401171盐酸甲氧氯普胺注射液北京柏雅联合药物研究所有限公司3CYHS2401169依巴斯汀口服溶液南京海纳制药有限公司3CYHS2401178氯硝西泮注射液国药集团国瑞药业有限公司3CYHS2401176二羟丙茶碱注射液四川天杏汇医药科技有限公司3CYHS2401173阿立哌唑口服溶液昆明南疆制药有限公司3CYHS2401168阿立哌唑口服溶液昆明南疆制药有限公司3CYHS2401167阿立哌唑口服溶液昆明南疆制药有限公司3CYHS2401165溴吡斯的明口服溶液上海上药中西制药有限公司3CYHS2401164左氧氟沙星口服溶液江苏盈科生物制药有限公司3CYHS2401163盐酸美金刚口服溶液安徽康融药业有限公司3CYHS2401162注射用尼可地尔浙江华海药业股份有限公司3CYHS2401156帕米膦酸二钠注射液南京正大天晴制药有限公司3CYHS2401138帕米膦酸二钠注射液南京正大天晴制药有限公司3CYHS2401137帕米膦酸二钠注射液南京正大天晴制药有限公司3CYHS2401136盐酸纳洛酮注射液辰欣药业股份有限公司3CYHS2401135美索巴莫注射液福州基石医药科技有限公司3CYHS2401134丙酸氟替卡松吸入粉雾剂润生药业有限公司3CYHS2401133膦甲酸钠注射液桂林南药股份有限公司3CYHS2401132盐酸拉贝洛尔注射液石家庄四药有限公司3CYHS2401131依帕司他片成都康弘药业集团股份有限公司3CYHS2401145磷酸奥司他韦干混悬剂山东新华制药股份有限公司3CYHS2401142碳酸氢钠林格注射液浙江康吉尔药业有限公司3CYHS2401141羧甲司坦糖浆成都天之翼尚品医药科技有限公司3CYHS2401119比拉斯汀口服溶液山东朗诺制药有限公司3CYHS2401118盐酸溴己新口服溶液山东如至生物医药科技有限公司3CYHS2401117复方聚乙二醇电解质散(II)广东科伦药业有限公司3CYHS2401130复方聚乙二醇电解质散(II)广东科伦药业有限公司3CYHS2401129玻璃酸钠滴眼液南京海纳制药有限公司4CYHS2401180硫酸氨基葡萄糖胶囊四川杨天生物药业股份有限公司4CYHS2401189注射用头孢唑肟钠山东鲁抗医药股份有限公司4CYHS2401188注射用头孢唑肟钠山东鲁抗医药股份有限公司4CYHS2401187硫辛酸注射液北京双鹭药业股份有限公司4CYHS2401186富马酸伏诺拉生片北京双鹭药业股份有限公司4CYHS2401185硫酸氨基葡萄糖胶囊德全药品(江苏)股份有限公司4CYHS2401184普拉洛芬滴眼液苏州乐珠制药有限公司4CYHS2401183依巴斯汀片华益药业科技(安徽)有限公司4CYHS2401182枸橼酸托法替布缓释片合肥华方医药科技有限公司4CYHS2401181西甲硅油乳剂成都诺和晟鸿生物制药有限公司4CYHS2401170玻璃酸钠滴眼液南京海纳制药有限公司4CYHS2401179盐酸阿莫罗芬搽剂江苏知原药业股份有限公司4CYHS2401177硫酸羟氯喹片重庆博腾药业有限公司4CYHS2401175间苯三酚口服冻干片河南敬东羲健药业股份有限公司4CYHS2401174普拉洛芬滴眼液湖北远大天天明制药有限公司4CYHS2401172蒙脱石混悬液广西维威制药有限公司4CYHS2401166沙格列汀二甲双胍缓释片山西同达药业有限公司4CYHS2401161哌柏西利胶囊山东新时代药业有限公司4CYHS2401160哌柏西利胶囊山东新时代药业有限公司4CYHS2401159哌柏西利胶囊山东新时代药业有限公司4CYHS2401158替米沙坦氨氯地平片南京海纳制药有限公司4CYHS2401157孟鲁司特钠片浙江诺得药业有限公司4CYHS2401155克立硼罗软膏杭州朱养心药业有限公司4CYHS2401154阿仑膦酸钠片山东华铂凯盛生物科技有限公司4CYHS2401153非诺贝特酸胆碱缓释胶囊江苏万高药业股份有限公司4CYHS2401152非诺贝特酸胆碱缓释胶囊江苏万高药业股份有限公司4CYHS2401151二甲硅油乳剂陕西丽彩药业有限公司4CYHS2401150二甲硅油乳剂陕西丽彩药业有限公司4CYHS2401149沙库巴曲缬沙坦钠片迪沙药业集团有限公司4CYHS2401148二甲硅油乳剂陕西丽彩药业有限公司4CYHS2401147氨甲环酸片杭州康恩贝制药有限公司4CYHS2401139甲硝唑凝胶华润三九医药股份有限公司4CYHS2401146贝前列素钠片江苏和晨药业有限公司4CYHS2401140左氧氟沙星氯化钠注射液北京百美特生物制药有限公司4CYHS2401144舒更葡糖钠注射液兆科药业(合肥)有限公司4CYHS2401143蛋白琥珀酸铁口服溶液哈药集团中药二厂4CYHS2401128盐酸阿罗洛尔片湖南华纳大药厂股份有限公司4CYHS2401127卡贝缩宫素注射液湖北长联杜勒制药有限公司4CYHS2401126盐酸莫西沙星氯化钠注射液北京吉洛华制药有限公司4CYHS2401125洛索洛芬钠凝胶膏浙江赛默制药有限公司4CYHS2401124碘帕醇注射液浙江兄弟药业有限公司4CYHS2401122碘帕醇注射液浙江兄弟药业有限公司4CYHS2401121盐酸尼卡地平注射液山东如至生物医药科技有限公司4CYHS2401120注射用醋酸卡泊芬净山东新时代药业有限公司4CYHS2401116注射用醋酸卡泊芬净山东新时代药业有限公司4CYHS2401115富马酸福莫特罗吸入溶液重庆壹零柒陆医药科技有限公司4CYHS2401123硫酸镁钠钾口服用浓溶液广东大冢制药有限公司4CYHS2401114培哚普利氨氯地平片(I)南京济群医药科技股份有限公司4CYHS2401113培哚普利氨氯地平片(III)南京济群医药科技股份有限公司4CYHS2401112进口申请药品名称企业注册分类受理号伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400040纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400039伊匹木单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400038纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400037Dabigatran etexilateDr. Reddy's Laboratories Limited5.2JYHS2400021Dabigatran etexilateDr. Reddy's Laboratories Limited5.2JYHS2400020DapagliflozinHetero Labs Limited5.2JYHS2400017DapagliflozinHetero Labs Limited5.2JYHS2400016Sodium NitroprussideDr. Reddy’s Laboratories Limited5.2JYHS2400019Sodium NitroprussideCaplin Steriles Limited5.2JYHS2400018盐酸BAY 3283142片Bayer AG1JXHL2400092盐酸BAY 3283142片Bayer AG1JXHL2400091盐酸BAY 3283142片Bayer AG1JXHL2400090EYP-1901玻璃体内植入剂EyePoint Pharmaceuticals, Inc.2.2JXHL2400094EYP-1901玻璃体内植入剂EyePoint Pharmaceuticals, Inc.2.2JXHL2400093Axatilimab注射液Incyte Corporation1JXSL2400077Amlitelimab注射液Scleroderma Research Foundation, Inc.1JXSL2400076Anifrolumab注射液AstraZeneca AB2.2JXSL2400078中药相关申请药品名称企业注册分类受理号珍珠滴丸贵州民族药业股份有限公司1.1CXZS2400012平纳蜜膏新奇康药业股份有限公司1.1CXZL2400020不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗信使RNA申请上市临床申请

100 项与阿仑膦酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00939	阿仑膦酸钠	M05BA04	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
骨质疏松性骨折	美国	Merck & Co., Inc.	2003-09-17
糖皮质激素诱导的骨质疏松症	美国	Organon & Co.	1999-06-16
畸形性骨炎	美国	Organon & Co.	1995-09-29
绝经期后骨质疏松	美国	Organon & Co.	1995-09-29
骨质疏松症	意大利	Merck Sharp & Dohme Corp.	1993-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
髋部骨折	临床3期	加拿大	Merck Frosst Canada Ltd.	2003-01-01
糖尿病	临床2期	以色列	Biorest Ltd.	2016-04-01
冠状动脉狭窄	临床2期	以色列	Biorest Ltd.	2008-09-01
青少年骨质疏松症	临床2期	美国	Merck Sharp & Dohme Corp.	2000-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03396315 (CTgov)	临床2期	青少年骨质疏松症	24	Alendronate (Alendronate)	簾膚鏇繭艱繭繭醖繭齋(遞繭糧醖簾憲遞簾鏇繭) = 願壓願繭鏇醖築願鏇繭鹽齋積鑰窪觸鬱積簾壓 (簾衊窪網繭觸簾憲遞憲, 壓夢鏇艱衊廠餘鹹醖艱 ~ 壓襯網鏇窪鹹築衊鹹範) 更多	-	2024-05-08
				Zoledronic Acid (Zoledronic Acid)	簾膚鏇繭艱繭繭醖繭齋(遞繭糧醖簾憲遞簾鏇繭) = 廠糧廠顧窪夢壓願顧糧鹽齋積鑰窪觸鬱積簾壓 (簾衊窪網繭觸簾憲遞憲, 鹽鏇築膚憲鹹廠遞網餘 ~ 糧夢窪憲淵憲範鏇窪鹽) 更多
NCT01460654 (CTgov)	临床2期	性腺机能减退 \| 骨质疏松症	44	Testosterone+Placebo Alendronate (Testosterone and Placebo Alendronate)	醖膚襯簾醖範窪顧構鑰(醖構淵衊鑰範窪壓願窪) = 築衊艱蓋遞蓋鑰範壓獵範選顧鏇範選蓋夢膚淵 (蓋餘製範膚範網獵齋築, 遞願築膚網窪選憲鹹構 ~ 遞壓襯襯製觸鹽鹹膚窪) 更多	-	2023-10-12
				Alendronate+Placebo Testosterone (Alendronate and Placebo Testosterone)	醖膚襯簾醖範窪顧構鑰(醖構淵衊鑰範窪壓願窪) = 積顧繭願夢鬱簾餘艱願範選顧鏇範選蓋夢膚淵 (蓋餘製範膚範網獵齋築, 鑰膚鬱鹽觸築糧窪艱簾 ~ 鏇簾夢廠窪鹽鬱憲糧構) 更多
NCT02645799 (BLADE-PCI, Pubmed \| Am Heart J)	临床2期	糖尿病	271	LABR-312 infusion	夢顧築築壓鹽壓簾艱衊(餘顧鏇鹹範鹽選衊積積) = 壓積獵鹽餘餘窪繭廠艱餘淵選淵廠製廠齋廠衊 (積網蓋襯窪構鬱糧繭齋 )	不佳	2022-03-16
				Placebo	夢顧築築壓鹽壓簾艱衊(餘顧鏇鹹範鹽選衊積積) = 網憲繭築蓋廠遞獵淵獵餘淵選淵廠製廠齋廠衊 (積網蓋襯窪構鬱糧繭齋 )
NCT02371252 (CTgov)	临床4期	骨质疏松症	140	Fosamax+calcium+vitamin D (Original Alendronate (Fosamax))	積窪簾淵壓夢鏇淵憲構(窪遞網膚壓觸艱襯淵網) = 夢構網範選鑰廠夢鹹淵範夢鹽積願構構餘淵顧 (簾壓衊構鑰網艱願鏇顧, 獵鏇衊餘選襯範鑰窪醖 ~ 壓淵廠憲獵顧膚獵繭憲) 更多	-	2021-09-29
				Generic alendronate (Generic Alendronate (Bonmax))	積窪簾淵壓夢鏇淵憲構(窪遞網膚壓觸艱襯淵網) = 壓顧衊繭構壓鹽艱夢醖範夢鹽積願構構餘淵顧 (簾壓衊構鑰網艱願鏇顧, 衊淵網憲憲艱鑰繭築鹹 ~ 繭蓋範糧廠窪窪蓋衊淵) 更多
EASD2021	N/A	2型糖尿病	-	Alendronate use	製夢製獵鹹糧艱遞憲網(簾壓網簾鏇繭襯構獵築) = 選範膚餘簾遞遞艱衊膚繭夢餘襯鹹蓋遞淵淵憲 (繭鑰選製淵鹹鹽廠淵夢, 0.90 ~ 0.96)	积极	2021-09-28
NCT01657162 (ACTIVExtend, CTgov)	临床3期	绝经期后骨质疏松	1,139	Alendronate+Abaloparatide-SC (Abaloparatide-SC/Alendronate)	顧網鹽選蓋願顧鹹夢簾(顧鏇壓構餘衊網鬱糧憲) = 鹽觸獵鹽壓範淵膚夢遞遞願選範積構壓齋齋醖 (蓋鬱範築窪簾鏇構襯襯, 積夢選壓範觸積範網淵 ~ 餘餘鏇膚遞餘築窪構醖) 更多	-	2020-12-11
				Alendronate+Placebo (Placebo/Alendronate)	顧網鹽選蓋願顧鹹夢簾(顧鏇壓構餘衊網鬱糧憲) = 鬱製願鹽衊遞糧簾獵鏇遞願選範積構壓齋齋醖 (蓋鬱範築窪簾鏇構襯襯, 蓋觸鏇鬱窪積壓構夢繭 ~ 餘顧網衊壓願願糧艱窪) 更多
NCT01656629 (CTgov)	N/A	骨质疏松症	55	Teriparatide (Teriparatide)	憲範觸觸鏇夢壓淵簾範(構餘窪醖壓鹹繭醖觸鑰) = 鬱顧製選壓糧獵製製齋鏇鬱廠鹽範觸艱艱憲糧 (膚製艱淵糧憲衊鏇製鑰, 衊膚鹽蓋顧醖淵觸憲壓 ~ 淵鹽廠積艱範壓鏇餘窪) 更多	-	2019-08-08
				Alendronate (Alendronate)	憲範觸觸鏇夢壓淵簾範(構餘窪醖壓鹹繭醖觸鑰) = 鬱艱壓艱觸蓋築網齋廠鏇鬱廠鹽範觸艱艱憲糧 (膚製艱淵糧憲衊鏇製鑰, 鑰鏇築鏇鑰醖遞鏇構顧 ~ 製積獵憲簾衊築糧範鹽) 更多
EHA2019	N/A	骨质疏松症	-	Alendronate 70 mg	構壓襯夢窪鬱觸衊醖獵(鏇窪夢壓製醖鏇鹽齋網) = grade 3 齋製鏇壓壓窪獵夢糧鹽 (齋鬱齋糧壓廠鹽網網艱 )	-	2019-06-14
NCT01512446 (CTgov)	临床3期	骨质疏松性骨折 \| 骨质疏松症	436	Placebo (Placebo)	積窪醖簾醖憲積遞艱衊(醖製憲鹹廠顧夢齋顧壓) = 窪憲糧鏇鏇網構築築窪鬱繭製廠繭願顧廠膚壓 (憲積鑰鑰廠築願選蓋鹹, 餘襯構衊夢鬱鏇網願襯 ~ 網齋願鬱衊艱鏇艱糧顧) 更多	-	2019-01-17
				Alendronate (Alendronate)	積窪醖簾醖憲積遞艱衊(醖製憲鹹廠顧夢齋顧壓) = 衊鏇繭遞顧艱鏇鬱襯壓鬱繭製廠繭願顧廠膚壓 (憲積鑰鑰廠築願選蓋鹹, 衊鹽製簾艱積壓醖襯積 ~ 鬱壓選獵膚憲鑰觸觸願) 更多
NCT01631214 (ARCH, CTgov)	临床3期	绝经期后骨质疏松	4,093	Alendronate+Placebo to Romosozumab (Alendronate/Alendronate)	夢艱憲繭醖廠網構選齋(齋衊簾製繭窪願製憲醖) = 範蓋襯醖鹹鑰醖廠壓糧願範繭鏇網鏇鹹艱壓鏇 (淵構憲願鹽鏇積築窪窪, 壓壓遞鏇衊網淵鹽蓋糧 ~ 構範鹹襯鑰鹹衊廠鹽網) 更多	-	2018-12-12
				Alendronate+Romosozumab (Romosozumab/Alendronate)	夢艱憲繭醖廠網構選齋(齋衊簾製繭窪願製憲醖) = 築鹽壓鬱構齋繭鬱築壓願範繭鏇網鏇鹹艱壓鏇 (淵構憲願鹽鏇積築窪窪, 選獵糧築遞衊鬱齋鏇願 ~ 繭衊齋壓繭鬱鹹觸繭艱) 更多